Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance

Hilal S. Khalil, Vanio Mitev, Tatyana Vlaykova, Laura Cavicchi, Nikolai Zhelev

Research output: Contribution to journalArticle

19 Citations (Scopus)
15 Downloads (Pure)

Abstract

Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone drug development and clinical testing as an anticancer agent. In this review, the authors describe the discovery of Seliciclib and give a brief summary of the biology of the CDKs Seliciclib inhibits. An overview of the published in vitro and in vivo work supporting the development as an anti-cancer agent, from in vitro experiments to animal model studies ending with a summary of the clinical trial results and trials underway is presented. In addition some potential non-oncology applications are explored and the potential mode of action of Seliciclib in these areas is described. Finally the authors argue that optimisation of the therapeutic effects of kinase inhibitors such as Seliciclib could be enhanced using a systems biology approach involving mathematical modelling of the molecular pathways regulating cell growth and division.
Original languageEnglish
Pages (from-to)40-49
Number of pages10
JournalJournal of Biotechnology
Volume202
Early online date6 Mar 2015
DOIs
Publication statusPublished - 20 May 2015

Fingerprint

Systems Biology
Pharmaceutical Preparations
Therapeutic Uses
Cell Division
Antineoplastic Agents
Action Potentials
roscovitine
Phosphotransferases
Animal Models
Clinical Trials
Growth
Neoplasms

Cite this

Khalil, Hilal S. ; Mitev, Vanio ; Vlaykova, Tatyana ; Cavicchi, Laura ; Zhelev, Nikolai. / Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance. In: Journal of Biotechnology. 2015 ; Vol. 202. pp. 40-49.
@article{42636ae896214115a004e6eb01a1568c,
title = "Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance",
abstract = "Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone drug development and clinical testing as an anticancer agent. In this review, the authors describe the discovery of Seliciclib and give a brief summary of the biology of the CDKs Seliciclib inhibits. An overview of the published in vitro and in vivo work supporting the development as an anti-cancer agent, from in vitro experiments to animal model studies ending with a summary of the clinical trial results and trials underway is presented. In addition some potential non-oncology applications are explored and the potential mode of action of Seliciclib in these areas is described. Finally the authors argue that optimisation of the therapeutic effects of kinase inhibitors such as Seliciclib could be enhanced using a systems biology approach involving mathematical modelling of the molecular pathways regulating cell growth and division.",
author = "Khalil, {Hilal S.} and Vanio Mitev and Tatyana Vlaykova and Laura Cavicchi and Nikolai Zhelev",
year = "2015",
month = "5",
day = "20",
doi = "10.1016/j.jbiotec.2015.02.032",
language = "English",
volume = "202",
pages = "40--49",
journal = "Journal of Biotechnology",
issn = "0168-1656",
publisher = "Elsevier Science B.V.",

}

Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance. / Khalil, Hilal S.; Mitev, Vanio; Vlaykova, Tatyana; Cavicchi, Laura; Zhelev, Nikolai.

In: Journal of Biotechnology, Vol. 202, 20.05.2015, p. 40-49.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance

AU - Khalil, Hilal S.

AU - Mitev, Vanio

AU - Vlaykova, Tatyana

AU - Cavicchi, Laura

AU - Zhelev, Nikolai

PY - 2015/5/20

Y1 - 2015/5/20

N2 - Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone drug development and clinical testing as an anticancer agent. In this review, the authors describe the discovery of Seliciclib and give a brief summary of the biology of the CDKs Seliciclib inhibits. An overview of the published in vitro and in vivo work supporting the development as an anti-cancer agent, from in vitro experiments to animal model studies ending with a summary of the clinical trial results and trials underway is presented. In addition some potential non-oncology applications are explored and the potential mode of action of Seliciclib in these areas is described. Finally the authors argue that optimisation of the therapeutic effects of kinase inhibitors such as Seliciclib could be enhanced using a systems biology approach involving mathematical modelling of the molecular pathways regulating cell growth and division.

AB - Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone drug development and clinical testing as an anticancer agent. In this review, the authors describe the discovery of Seliciclib and give a brief summary of the biology of the CDKs Seliciclib inhibits. An overview of the published in vitro and in vivo work supporting the development as an anti-cancer agent, from in vitro experiments to animal model studies ending with a summary of the clinical trial results and trials underway is presented. In addition some potential non-oncology applications are explored and the potential mode of action of Seliciclib in these areas is described. Finally the authors argue that optimisation of the therapeutic effects of kinase inhibitors such as Seliciclib could be enhanced using a systems biology approach involving mathematical modelling of the molecular pathways regulating cell growth and division.

U2 - 10.1016/j.jbiotec.2015.02.032

DO - 10.1016/j.jbiotec.2015.02.032

M3 - Article

VL - 202

SP - 40

EP - 49

JO - Journal of Biotechnology

JF - Journal of Biotechnology

SN - 0168-1656

ER -